Parapharm homeopatijos vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 288,386 | 261,051 | 290,037 | 532,637 | 573,968 | 619,211 | 731,729 | 743,383 |
| Profit before tax | - | - | - | - | - | - | 53,401 | 50,427 |
| Net profit | -18,202 | 4,862 | 55,933 | 14,285 | 16,913 | 11,615 | 44,752 | 41,578 |
| Equity | -15,039 | 19,173 | 70,095 | 83,920 | 100,833 | 108,500 | 151,417 | 191,161 |
| Liabilities | 98,446 | 61,032 | 45,620 | 62,560 | 78,231 | 88,919 | 68,917 | 51,650 |
| Non-current assets | 30,579 | 50,719 | 44,459 | 46,451 | 60,174 | 49,852 | 39,603 | 33,272 |
| Current assets | 52,780 | 29,443 | 71,222 | 99,794 | 118,516 | 147,374 | 179,965 | 209,374 |
| Total assets | 83,359 | 80,162 | 115,681 | 146,245 | 178,690 | 197,226 | 219,568 | 242,646 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 98,938 | 119,545 | 144,250 |
| Social insurance contributions | - | - | - | - | - | 45,670 | 51,535 | 56,902 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +4.5% | -9.5% | +11.1% | +83.6% | +7.8% | +7.9% | +18.2% | +1.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -21.8% | 6.1% | 48.4% | 9.8% | 9.5% | 5.9% | 20.4% | 17.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 25.4% | 79.8% | 17.0% | 16.8% | 10.7% | 29.6% | 21.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -6.3% | 1.9% | 19.3% | 2.7% | 2.9% | 1.9% | 6.1% | 5.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 7.3% | 6.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 3.2 | 0.7 | 0.7 | 0.8 | 0.8 | 0.5 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 32,648 | 44,752 | 64,453 | 55,100 | 52,577 | 58,051 | 66,521 | 69,152 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Parapharm homeopatijos vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-05-02 | 2023-05-08 | 1.09 |
| 2023-04-20 | 2023-04-28 | 1.09 |
| 2022-04-19 | 2022-05-09 | 3.67 |
| 2022-03-16 | 2022-03-17 | 1010.56 |
| 2022-01-18 | 2022-01-19 | 163.78 |
Parapharm homeopatijos vaistinė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-10 | 2025-05-12 | 0.01 |
| 2025-05-05 | 2025-05-09 | 17.59 |
| 2025-05-03 | 2025-05-04 | 17.96 |
| 2025-05-01 | 2025-05-02 | 35.95 |
| 2025-04-02 | 2025-04-11 | 14.61 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Parapharm, UAB (code 135877483) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €743.4K and net profit of €41.6K, corresponding to a profit margin of 5.6%. Revenue increased by 1.6% year on year and by 20.1% over two years, showing steady expansion. The revenue trajectory moved from €619.2K in 2023 to €731.7K in 2024 and further to €743.4K in 2025. Profitability improved materially from €11.6K in 2023 to €44.8K in 2024, then remained solid in 2025 despite a modest decline. The balance sheet also strengthened: total assets reached €242.6K, equity €191.2K and liabilities €51.6K in 2025. Key indicators point to a strong capital structure, with an equity ratio of 78.8% and debt-to-equity of 0.27. Return on equity stood at 21.8% and return on assets at 17.1%, while asset turnover was 3.06x. Revenue per employee was €74.3K and profit per employee €4.2K.